Eric Johnston, chief equity and macro strategist at Cantor Fitzgerald, said he believes stocks are in for a tactical ...

We are entering the buy zone for the momentum factor (BATS:MTUM), , according to Eric Johnston, chief equity and macro ...

Cantor Fitzgerald announced Anchorage Digital, Copper.co will serve as collateral managers and custodians for the firm's ...

This summary is reviewed by TRD Staff. Howard Lutnick stepped down from Cantor Fitzgerald after being confirmed as Commerce Secretary. Lutnick's sons, Brandon and Kyle Lutnick, were appointed to ...

Cantor Fitzgerald currently has a $8.00 price objective on the stock. Cantor Fitzgerald also issued estimates for EVgo’s FY2025 earnings at ($0.33) EPS. Other equities research analysts also ...

Cantor Fitzgerald analyst P. Agrawal expects that the biotechnology company will post earnings of ($0.54) per share for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock.

Cantor Fitzgerald analyst C.J. Muse initiated coverage of SanDisk with an Overweight rating and $60 price target. Cantor Fitzgerald initiated coverage of SanDisk (SNDK) with an Overweight rating ...

Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share.

Mesoblast Limited (NASDAQ:MESO – Free Report) – Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Mesoblast in a note issued to investors on Tuesday, March 4th.